A phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with metastatic melanoma.

Trial Profile

A phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with metastatic melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms BEAM
  • Sponsors Genentech
  • Most Recent Events

    • 28 Nov 2011 Primary endpoint 'Progression-free-survival' has not been met.
    • 27 Sep 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 27 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top